STAT+: Pharmalittle: We’re reading about an HHS peptide push, Trump’s pharma stock holdings, and more

The week is coming to a close, and we find ourselves reflecting on the day's events. For many, the opportunity to unwind and engage in leisure activities is a welcome respite. It is anticipated that a listening party will be held, featuring a variety of playlists. Amidst the world's distractions, taking a break to appreciate nature, such as visiting an apple orchard or pumpkin patch, can be rejuvenating.

Hydration during these outings might involve apple cider, especially if weather conditions permit. Alternatively, indoor entertainment options like watching television shows or preparing a delicious meal can be considered. The option to spend quality time with a loved one is also suggested. Regardless of the chosen activity, it is emphasized that safety should be prioritized.

As the story continues, it highlights the Trump administration's initiative to permit compounding pharmacies to manufacture certain peptides, which are largely unregulated injections gaining popularity among certain wellness advocates. These peptides, not approved by the FDA, are primarily supported by data from animal studies. Meanwhile, China is contemplating stricter regulations on biotechnology exports but is open to licensing agreements with foreign pharmaceutical companies, maintaining its status as a rising pharmaceutical leader. The full story can be found at STAT+.